Master Manufacturing Services Agreement August 3, 2015Master Manufacturing Services Agreement • February 28th, 2024 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS AGREEMENT WITNESSES THAT in consideration of the rights conferred and the obligations assumed herein, and for other good and valuable consideration (the receipt and sufficiency of which are acknowledged by each Party), and intending to be legally bound the Parties agree as follows:
PRODUCT AGREEMENTProduct Agreement • February 28th, 2024 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations
Pursuant to the Master Manufacturing Services Agreement dated August 3, 2015 between Patheon Pharmaceuticals Inc., and Acadia Pharmaceuticals Inc., as amended January 1, 2022 (collectively the “Master Agreement”), this Product Agreement (this “Product Agreement” or “PA”) is effective as of May 1, 2022 (the “Effective Date”), and is entered into by Acadia Pharmaceuticals Inc., a Delaware corporation having its principal place of business at 12830 El Camino Real, Suite 400, San Diego, California 92130 ( “Acadia” or “Client”), and Patheon Pharmaceuticals Inc., having a principal place of business at 2110 East Galbraith Road, Cincinnati, OH 45237( “Patheon”) on behalf of itself and its Affiliates, as defined in Section 1.3 of the Master Agreement) within the Thermo Fisher Scientific Inc. Pharma Services Group. Patheon and Acadia may be collectively referred to as the parties and individually as a party.
MASTER COMMERCIAL SUPPLY AGREEMENTCommercial Supply Agreement • February 28th, 2024 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations
THIS COMMERCIAL SUPPLY AGREEMENT (the “Agreement” or this “CSA”) is made and entered into the 16th day of November , 2022 (the “Effective Date”), by and between Corden Pharma Bergamo S.p.A., having a place of business at Via Bergamo 121, 24047 Treviglio (BG), Italy (“Corden”), and Acadia Pharmaceuticals, Inc., a Delaware corporation with offices at 3611 Valley Centre Drive, Ste. 300, San Diego, CA 92130 (“Customer”). Corden and Customer, as used herein, may be referred to, collectively, as the “Parties” and individually as a “Party”.
First Amendment to Product Agreement between Patheon Pharmaceuticals Inc. and ACADIA Pharmaceuticals Inc.Product Agreement • February 28th, 2024 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations
This First Amendment to Product Agreement (the “Amendment”), dated April 25, 2016 (the “Amendment Date”), is made by and between Patheon Pharmaceuticals Inc. (“Patheon”) and ACADIA Pharmaceuticals Inc. (“ACADIA”).
Second Amendment to Product Agreement between Patheon Pharmaceuticals Inc. and ACADIA Pharmaceuticals Inc.Product Agreement • February 28th, 2024 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations
This Second Amendment to Product Agreement (the “Amendment”), dated October 6, 2016 (the “Amendment Date”), is made by and between Patheon Pharmaceuticals Inc. (“Patheon”) and ACADIA Pharmaceuticals Inc. (“ACADIA”).
Third Amendment to Product Agreement between Patheon Pharmaceuticals Inc. and ACADIA Pharmaceuticals Inc.Product Agreement • February 28th, 2024 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations
This Third Amendment to Product Agreement (this “Amendment”), dated December 11, 2017 (the “Amendment Date”), is made by and between Patheon Pharmaceuticals Inc. (“Patheon”) and ACADIA Pharmaceuticals Inc. (“ACADIA”).
Commercial Supply AgreementCommercial Supply Agreement • February 28th, 2024 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations
Acadia (and its Affiliates) engages in the business of research, development and commercialization of pharmaceutical compounds and products;
COMMERCIAL SUPPLY AGREEMENTCommercial Supply Agreement • February 28th, 2024 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
This Commercial Supply Agreement is made as of this 1st day of March, 2023 (the “Effective Date”), by and between ACADIA Pharmaceuticals Inc., a Delaware corporation, with a place of business at 12830 El Camino Real, Suite 400, San Diego, California 92130 (“Client”), and CoreRx Inc, a Florida corporation, having a place of business at 14205 Myerlake Circle, Clearwater, FL 33760 (“CoreRx” or “Supplier” ). Client and CoreRx may individually be referred to as a “party” and collectively as the “parties.”
